Cargando…
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
INTRODUCTION: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309124/ https://www.ncbi.nlm.nih.gov/pubmed/35689161 http://dx.doi.org/10.1007/s12325-022-02202-5 |
_version_ | 1784753088993689600 |
---|---|
author | Woolley, Michael Cook, Erin E. Mu, Fan Betts, Keith A. Billmyer, Emma Yim, Erica Chen, Jingyi Wu, Eric Q. |
author_facet | Woolley, Michael Cook, Erin E. Mu, Fan Betts, Keith A. Billmyer, Emma Yim, Erica Chen, Jingyi Wu, Eric Q. |
author_sort | Woolley, Michael |
collection | PubMed |
description | INTRODUCTION: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients with EoG/EoN versus without EoG/EoN in the USA. METHODS: Administrative claims data from the IBM MarketScan(®) Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits Databases (2009–2019) was used to identify two cohorts of patients. Patients without EoG/EoN were matched 3:1 to patients with EoG/EoN on sex, year of birth, and healthcare plan type. Study measures included demographic characteristics, select comorbidities, all-cause HRU, and costs. Comparisons were made over a 1-year period following EoG/EoN diagnosis for patients with EoG/EoN and an eligible date for patients without EoG/EoN. RESULTS: A total of 2219 patients with EoG/EoN and 6657 patients without EoG/EoN were analyzed. Significantly higher proportions of patients with EoG/EoN versus without EoG/EoN had comorbid conditions. Rates of all-cause HRU were significantly higher among patients with EoG/EoN versus patients without EoG/EoN (adjusted rate ratio [95% confidence interval]: inpatient visits, 6.26 [5.26, 7.46]; outpatient visits, 1.17 [1.16, 1.19]; emergency department visits, 2.11 [1.98, 2.25]; all p < 0.001). Patients with EoG/EoN incurred significantly higher costs versus patients without EoG/EoN (adjusted mean cost difference $31,180; p < 0.001). Cost differences were largely due to outpatient (adjusted mean cost difference $14,018; p < 0.001) and inpatient (adjusted mean cost difference $11,224; p < 0.001) costs. CONCLUSION: The economic burden associated with EoG/EoN is substantial, with patients with EoG/EoN having a higher rate of HRU and incurring $31,180 more than patients without EoG/EoN on average. Most of the cost difference was attributable to outpatient and inpatient costs. Cost-saving strategies to lower the burden of illness in this patient population are needed. |
format | Online Article Text |
id | pubmed-9309124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-93091242022-07-26 The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States Woolley, Michael Cook, Erin E. Mu, Fan Betts, Keith A. Billmyer, Emma Yim, Erica Chen, Jingyi Wu, Eric Q. Adv Ther Original Research INTRODUCTION: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients with EoG/EoN versus without EoG/EoN in the USA. METHODS: Administrative claims data from the IBM MarketScan(®) Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits Databases (2009–2019) was used to identify two cohorts of patients. Patients without EoG/EoN were matched 3:1 to patients with EoG/EoN on sex, year of birth, and healthcare plan type. Study measures included demographic characteristics, select comorbidities, all-cause HRU, and costs. Comparisons were made over a 1-year period following EoG/EoN diagnosis for patients with EoG/EoN and an eligible date for patients without EoG/EoN. RESULTS: A total of 2219 patients with EoG/EoN and 6657 patients without EoG/EoN were analyzed. Significantly higher proportions of patients with EoG/EoN versus without EoG/EoN had comorbid conditions. Rates of all-cause HRU were significantly higher among patients with EoG/EoN versus patients without EoG/EoN (adjusted rate ratio [95% confidence interval]: inpatient visits, 6.26 [5.26, 7.46]; outpatient visits, 1.17 [1.16, 1.19]; emergency department visits, 2.11 [1.98, 2.25]; all p < 0.001). Patients with EoG/EoN incurred significantly higher costs versus patients without EoG/EoN (adjusted mean cost difference $31,180; p < 0.001). Cost differences were largely due to outpatient (adjusted mean cost difference $14,018; p < 0.001) and inpatient (adjusted mean cost difference $11,224; p < 0.001) costs. CONCLUSION: The economic burden associated with EoG/EoN is substantial, with patients with EoG/EoN having a higher rate of HRU and incurring $31,180 more than patients without EoG/EoN on average. Most of the cost difference was attributable to outpatient and inpatient costs. Cost-saving strategies to lower the burden of illness in this patient population are needed. Springer Healthcare 2022-06-10 2022 /pmc/articles/PMC9309124/ /pubmed/35689161 http://dx.doi.org/10.1007/s12325-022-02202-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Woolley, Michael Cook, Erin E. Mu, Fan Betts, Keith A. Billmyer, Emma Yim, Erica Chen, Jingyi Wu, Eric Q. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States |
title | The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States |
title_full | The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States |
title_fullStr | The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States |
title_full_unstemmed | The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States |
title_short | The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States |
title_sort | economic burden of eosinophilic gastritis and eosinophilic enteritis in the united states |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309124/ https://www.ncbi.nlm.nih.gov/pubmed/35689161 http://dx.doi.org/10.1007/s12325-022-02202-5 |
work_keys_str_mv | AT woolleymichael theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT cookerine theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT mufan theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT bettskeitha theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT billmyeremma theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT yimerica theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT chenjingyi theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT wuericq theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT woolleymichael economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT cookerine economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT mufan economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT bettskeitha economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT billmyeremma economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT yimerica economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT chenjingyi economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates AT wuericq economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates |